Lucira Health Inc Quick Ratio (LHDX) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lucira Health Inc   (NASDAQ: LHDX)

Lucira Health Inc 's Quick Ratio

LHDX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 0.5 a new company low.

Within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Lucira Health Inc in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 2082 to 3407.

Explain Quick Ratio?
How much Cash & cash equivalents LHDX´s has?
What are LHDX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LHDX Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change 192.33 % 94.67 % 295.69 % 484.36 % -
Y / Y Cash & cash equivalent Change -66.09 % -53.63 % -36.49 % 82.06 % -
Quick Ratio MRQ 0.5 1.34 1.76 2.11 4.27
LHDX's Total Ranking # 3407 # 2082 # 1818 # 1646 # 1055
Seq. Current Liabilities Change 43.88 % -18.68 % 36.19 % 83.45 % -4.19 %
Seq. Cash & cash equivalent Change -46.94 % -37.82 % 13.75 % -9.64 % -27.45 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 17
Healthcare Sector # 1050
Overall Market # 3407


Quick Ratio Statistics
High Average Low
10.96 4.17 0.5
(Mar 31 2021)   (Sep 30 2022)




Financial Statements
Lucira Health Inc 's Current Liabilities $ 80 Millions Visit LHDX's Balance sheet
Lucira Health Inc 's Cash & cash equivalent $ 40 Millions Visit LHDX's Balance sheet
Source of LHDX's Sales Visit LHDX's Sales by Geography


Cumulative Lucira Health Inc 's Quick Ratio

LHDX's Quick Ratio for the trailling 12 Months

LHDX Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 210.74 % 270.26 % 574.54 % 1336.49 % -
Y / Y Cash & cash equivalent TTM Growth -35.24 % 2.22 % 103.8 % 887.33 % -
Quick Ratio TTM 1.34 2.07 2.89 4.65 6.43
Total Ranking TTM # 4553 # 1430 # 1212 # 900 # 4350
Seq. Current Liabilities TTM Growth 26.12 % 15.5 % 41.4 % 50.87 % 50.28 %
Seq. Cash & cash equivalent TTM Growth -18.51 % -17.15 % -12.05 % 9.06 % 28.63 %

Quick ratio ranking by company, industry and sector >> Back to LHDX Financial Strength Comparisons >> Go to Compare LHDX Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2022 to $80.21 millions, cumulative Quick Ratio decreased to 1.34 below the Lucira Health Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 20 other companies have achieved higher Quick Ratio than Lucira Health Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 1430 to 4553.

Explain Quick Ratio?
How much Cash & cash equivalents LHDX´s has?
What are LHDX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 21
Healthcare Sector # 1177
Within the Market # 4553


trailing twelve months Quick Ratio Statistics
High Average Low
4.63 2.92 1.31
(Dec 31 2021)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Myriad Genetics Inc   1.34 $ 191.200  Millions$ 142.800  Millions
Lantheus Holdings Inc   1.09 $ 257.259  Millions$ 235.984  Millions
Volitionrx Limited  0.97 $ 16.416  Millions$ 16.978  Millions
Quotient Limited  0.92 $ 27.009  Millions$ 29.499  Millions
Nymox Pharmaceutical Corporation  0.68 $ 1.431  Millions$ 2.107  Millions
Navidea Biopharmaceuticals Inc   0.55 $ 4.601  Millions$ 8.433  Millions
Lucira Health Inc   0.50 $ 39.774  Millions$ 80.205  Millions
Trinity Biotech Plc  0.49 $ 8.412  Millions$ 17.339  Millions
Quidelortho Corp  0.30 $ 264.000  Millions$ 872.700  Millions
Cardio Diagnostics Holdings Inc   0.28 $ 0.178  Millions$ 0.632  Millions

Date modified: 2026-09-08T15:10:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.